Scholarlink

Introduction <p>Psoriasis vulgaris (PsV) is a chronic, immune-mediated skin disorder that significantly impairs quality of life and often necessitates long-term systemic therapy, especially in moderate-to-severe cases. In Japan, biologic agents targeting interleukin-17 (IL-17) have become central to the management of PsV; however, real-world evidence on their long-term persistence and associated factors remains limited.</p> Methods <p>This retrospective study utilized the Medical Data Vision database to evaluate treatment persistence of IL-17 inhibitors (ixekizumab, secukinumab, brodalumab, or bimekizumab) and factors associated with treatment persistence in Japanese patients with PsV. Patients aged ≥ 15&#xa0;years with a confirmed diagnosis of PsV and at least one claim of an IL-17 inhibitor between February 2015 and October 2023 were included. Persistence rates of IL-17 inhibitors (including ixekizumab) and ixekizumab were analyzed using the Kaplan–Meier method. Cox proportional hazard regression models were also used to calculate hazard ratios for factors associated with the treatment persistence of IL-17 inhibitors and ixekizumab.</p> Results <p>The persistence rates at 48&#xa0;months among patients treated with IL-17 inhibitors (<i>n</i> = 2904) and ixekizumab (<i>n</i> = 1105) were 52.4% and 41.2%, respectively. Similar rates were observed for ixekizumab dosing Q2/Q2 (46.9%) and Q2/Q4 (48.1%). Gender was a factor influencing treatment persistence in the IL-17 inhibitor cohort; however, no such association was observed in the ixekizumab cohort. Prior biologic experience was associated with shorter persistence for both IL-17 inhibitors and ixekizumab. No other demographic or clinical factors showed a significant association. Following ixekizumab treatment, use of phototherapy, topical, and systemic therapies declined, suggesting a shift toward biologic monotherapy.</p> Conclusions <p>These findings provide real-world evidence of the sustained use of IL-17 inhibitors in Japanese patients with PsV. Persistence showed no significant association with patient characteristics such as age, comorbidities, and concomitant medications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment Persistence of Interleukin-17 Inhibitors and Factors Associated with Persistence in Patients with Psoriasis Vulgaris in Japan: Retrospective Database Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月2日

查看全文
  • Yayoi Tada,
  • Hideaki Kagitani,
  • Shuichi Kimura,
  • Naoto Tsujimoto,
  • Kiyotaka Mochizuki

摘要

Introduction

Psoriasis vulgaris (PsV) is a chronic, immune-mediated skin disorder that significantly impairs quality of life and often necessitates long-term systemic therapy, especially in moderate-to-severe cases. In Japan, biologic agents targeting interleukin-17 (IL-17) have become central to the management of PsV; however, real-world evidence on their long-term persistence and associated factors remains limited.

Methods

This retrospective study utilized the Medical Data Vision database to evaluate treatment persistence of IL-17 inhibitors (ixekizumab, secukinumab, brodalumab, or bimekizumab) and factors associated with treatment persistence in Japanese patients with PsV. Patients aged ≥ 15 years with a confirmed diagnosis of PsV and at least one claim of an IL-17 inhibitor between February 2015 and October 2023 were included. Persistence rates of IL-17 inhibitors (including ixekizumab) and ixekizumab were analyzed using the Kaplan–Meier method. Cox proportional hazard regression models were also used to calculate hazard ratios for factors associated with the treatment persistence of IL-17 inhibitors and ixekizumab.

Results

The persistence rates at 48 months among patients treated with IL-17 inhibitors (n = 2904) and ixekizumab (n = 1105) were 52.4% and 41.2%, respectively. Similar rates were observed for ixekizumab dosing Q2/Q2 (46.9%) and Q2/Q4 (48.1%). Gender was a factor influencing treatment persistence in the IL-17 inhibitor cohort; however, no such association was observed in the ixekizumab cohort. Prior biologic experience was associated with shorter persistence for both IL-17 inhibitors and ixekizumab. No other demographic or clinical factors showed a significant association. Following ixekizumab treatment, use of phototherapy, topical, and systemic therapies declined, suggesting a shift toward biologic monotherapy.

Conclusions

These findings provide real-world evidence of the sustained use of IL-17 inhibitors in Japanese patients with PsV. Persistence showed no significant association with patient characteristics such as age, comorbidities, and concomitant medications.